

Clariant adopts THxID-BRAF, 5/14

April 2014—BioMérieux's molecular diagnostic test THxID-BRAF has been added to the offerings provided by Clariant, a GE Healthcare company. Clariant will use THxID-BRAF to aid oncologists in selecting metastatic melanoma patients whose tumors carry the BRAF V600E mutation for possible treatment with GlaxoSmithKline's Tafenlar (dabrafenib) and in selecting melanoma patients whose tumors carry the BRAF V600E or V600K mutation for possible treatment with Mekinist (trametinib). The assay is the only test able to simultaneously detect the two prevalent BRAF mutations, V600E and V600K.

[**GE Healthcare**](#), 609-514-6346

[**BioMérieux**](#), 919-620-2937